Strong Genetic

Tay-Sachs Disease

Name: Tay-Sachs Disease
Creator: Realised
Published: 2026-03-01

GeneHEXArsIDrs28940868, rs121907953, rs121907955InheritanceAutosomal recessiveCarrier frequency~1 in 30 Ashkenazi Jewish; ~1 in 20 French Canadian (Saguenay-Lac-Saint-Jean); ~1 in 300 general populationSystemCarrier Screening

Summary

Tay-Sachs disease is a progressive neurodegenerative condition caused by the buildup of a fatty substance (GM2 ganglioside) in the brain. In the classic infantile form, children appear healthy at birth but begin losing motor and cognitive function around 6 months of age, with death typically occurring by age 4-5. There is no treatment or cure for the infantile form. A milder adult-onset form (associated with the G269S variant) causes progressive neurological symptoms beginning in the teens or twenties, including muscle weakness, speech difficulties, and psychiatric symptoms.

Practical takeaway

This matters when you are planning children. If you carry a HEXA variant, your partner should be tested before or early in pregnancy. Partner testing can be done through a GP referral to a clinical genetics service, or through expanded carrier screening panels offered by clinical laboratories. A genetic counsellor can walk you both through the specific results, what they mean for your family, and what reproductive options exist. Realised does not replace that conversation — it flags that you should have it.

Evidence detail

What Carrier Status Means For You

You are not affected by Tay-Sachs disease. You carry one working copy and one non-working copy of the HEXA gene, which is enough for normal hexosaminidase A enzyme function. Your children could be affected only if your partner also carries a pathogenic HEXA variant — in that case, each pregnancy carries a 25% chance of the child being affected, a 50% chance of the child being a carrier like you, and a 25% chance of the child inheriting no variants.

Population Context

Tay-Sachs carrier frequency varies dramatically by ancestry. The high rate in Ashkenazi Jewish populations (~1 in 30) is thought to result from a founder effect — a small ancestral population carrying the variant expanded over centuries. A similar pattern exists in French Canadians from the Saguenay-Lac-Saint-Jean region (~1 in 20) and in some Cajun communities in Louisiana. In the general population, carrier frequency is roughly 1 in 300. These are population-level statistics, not individual predictions — carrier status crosses all ethnic boundaries.

Carrier screening programs in the Ashkenazi Jewish community, begun in the 1970s, reduced Tay-Sachs incidence by over 90%. This is one of the most successful genetic screening initiatives in history and demonstrates the value of carrier awareness.

Limitations

23andMe tests 4 of the over 130 known pathogenic HEXA variants. These 4 capture the most common mutations in Ashkenazi Jewish and French Canadian populations but miss rarer variants. A "not detected" result on a consumer chip does not mean zero carrier risk — it means the most common variants were not found. Clinical carrier screening (enzyme assay or comprehensive sequencing) covers far more variants and is the standard of care for individuals with a family history or those in high-frequency populations. If you have Ashkenazi Jewish or French Canadian ancestry and tested negative on a consumer chip, clinical confirmation is still recommended.

Sources (4)

Open in the Library: search, filter, every entry →